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METΔ7−8. METΔ7−8 is located predominantly in the cyto-
sol and is constitutively active. The auto-activating nature 
of METΔ7−8, in combination with a lack of transmembrane 
localization, renders METΔ7−8 not targetable using anti-
bodies, although the protein is efficiently deactivated by 
MET-specific tyrosine kinase inhibitors. Testing of MET-
expressing tumors for the presence of this variant may be 
important for treatment decision making.
Keywords MET · Glioma · Mutation · Protein 
localization · Genetic deletion · Auto-active · Intracellular 
location · Biomarker
Introduction
The MET proto-oncogene (chromosome 7q31.2) encodes 
the tyrosine kinase membrane receptor MET (also called 
Scatter Factor Receptor), which is essential during devel-
opment. Signaling from the receptor controls epithelial-
to-mesenchymal transition (EMT) of myogenic precursor 
cells during differentiation into skeletal muscle cells [5], a 
process that involves migration over long distances in the 
embryo. In adults, MET is involved in tissue regeneration 
upon injury [6].
MET is produced as a glycosylated single-chain pre-
cursor protein of ~190 kDa which, during transport to the 
membrane, undergoes furin-mediated cleavage in the trans-
Golgi network [8, 29]. The resulting mature receptor con-
sists of an extracellular 50 kDa α-chain, covalently attached 
via a disulfide bond to a membrane-spanning 140 kDa 
β-chain [20, 56]. The extracellular segment consists of an 
N-terminal Sema domain that is involved in ligand bind-
ing, a small cysteine-rich domain, and four IPT (Immu-
noglobulin-like fold shared by plexins and transcription 
Abstract MET has gained interest as a therapeutic target 
for a number of malignancies because of its involvement 
in tumorigenesis, invasion and metastasis. At present, a 
number of inhibitors, both antibodies against MET or its 
ligand hepatocyte growth factor, and small molecule MET 
tyrosine kinase inhibitors are in clinical trials. We here 
describe a novel variant of MET that is expressed in 6 % 
of high-grade gliomas. Characterization of this mutation 
in a glioma cell line revealed that it consists of an intronic 
deletion, resulting in a splice event connecting an intact 
splice donor site in exon 6 with the next splice acceptor 
site being that of exon 9. The encoded protein lacks parts 
of the extracellular IPT domains 1 and 2, encoded by exons 
7 and 8, resulting in a novel pseudo-IPT and is named 
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factors) domains, which connect the Sema and cysteine-
rich domains with the C-terminal β-subunit [18].
Upon binding of the ligand hepatocyte growth factor 
(HGF, scatter factor), receptor dimerization occurs fol-
lowed by trans-phosphorylation in the intracellular tyrosine 
kinase (TK) domain at tyrosine (Y) residues 1230, 1234 
and 1235 [14, 34]. The TK domain subsequently induces 
auto-phosphorylation of Y1349 and Y1356, which act as 
docking sites for signal transduction molecules includ-
ing GAB1, GRB2, phospholipase-C and SRC [50]. Phos-
phorylated GAB1 interacts with molecules like PI3-K and 
SHP2, which together induce several downstream signaling 
pathways. MET signaling is mediated by, among others, the 
PI3-K/AKT and RAS/MAPK pathways, which induce cell 
cycle progression, survival, cytoskeletal changes and inva-
sion (reviewed in [17]). In addition to its role downstream 
of HGF, MET can also be involved in signaling of other 
transmembrane receptors, including VEGFR2, CD44v6, 
EGFR and Plexin B1 [19, 26, 35, 44]. Upon ligand-induced 
receptor dimerization, MET is internalized via endocytosis 
and may be recycled [27]. Phosphorylation of Y1003 in the 
juxtamembrane (JM) domain of the receptor leads to ubiq-
uitination and subsequent proteasomal degradation [25]. 
Thus, levels of MET in the cell are tightly regulated.
Aberrant activation of MET signaling is a tumor-promot-
ing event in a variety of malignancies and can be induced 
by several mechanisms, including alternative mRNA splic-
ing, exon skipping and crosstalk with other receptors [13]. 
In high-grade gliomas, the frequently occurring oncogenic 
EGFR mutant EGFRvIII can induce overexpression of both 
MET and HGF, a process that is balanced by wild-type 
EGFR activation [33]. MET amplifications have been found 
in a number of tumor types including glioblastoma (GBM) 
[9, 10] and missense mutations in the Sema, the TK and 
the JM domain have been reported to affect HGF binding, 
kinase activation and receptor degradation, respectively [1, 
30, 32, 36, 38, 43, 48, 49]. Recently, gene fusions between 
the protein tyrosine phosphatase PTPRZ1 and MET, result-
ing in constitutive activation of MET, were described in 
16 % of secondary GBMs [2]. Activation of MET signaling 
has been proposed as a mechanism of resistance to EGFR 
inhibitors, likely a result of the similarities in downstream 
signaling events from both receptors [3].
The significant role that MET plays in tumor progres-
sion and metastasis has made it a prime therapeutic target 
in oncology. MET tyrosine kinase inhibitors and thera-
peutic antibodies against the extracellular domain of MET 
and against HGF, all preventing HGF-mediated MET acti-
vation, are currently in clinical trial (www.clinicaltrials.
gov). In a previous study, we have shown that the combined 
VEGFR2/MET tyrosine kinase inhibitor cabozantinib (XL-
184, CoMETRIQ) potently inhibits MET phosphorylation, 
cell proliferation and migration and consequently prolongs 
survival of mice carrying orthotopic E98 glioma xenografts 
[42]. Here, we identify a novel intragenic MET deletion in 
E98 cells, which results in a truncated protein that is consti-
tutively active and lacks membranous expression, thereby 
having important implications for therapeutic strategies tar-
geting MET. We show that this mutation occurs in 6 % of 
glioblastomas and, like the EGFR mutation EGFRvIII [4], 
is relatively specific for this tumor type.
Materials and methods
Immunohistochemistry
Immunohistochemistry on formalin-fixed, paraffin-embed-
ded (FFPE) tissue sections was performed as previously 
described using antibodies against MET and P-MET (clone 
D1C2 and D26, respectively, both CST) [42]. Antibodies 
were visualized via sequential incubations with biotinylated 
secondary antibodies, avidin–biotin complexes (Vector 
laboratories, Burlingame, CA, USA) and 3,3′-diaminoben-
zidine solution (Power-DAB, ImmunoLogic, Duiven, The 
Netherlands).
Cell lines
The E98 cell line and xenograft model and genetic analy-
sis thereof have been described before [12, 42]. E98, U87, 
A549, HEK-293T and TOV-112D or TOV-112D-MET cells 
[22] were cultured in DMEM + 4.5 g/l glucose medium 
(PAA Laboratories, Pasching, Austria) supplemented 
with 10 % fetal calf serum (FCS) (PAA) and gentamycin 
(40 μg/ml). All cell lines were maintained at 37 °C in the 
presence of 5 % CO2. To examine HGF-induced MET acti-
vation, E98 and A549 cells were seeded in 6 wells plates. 
The next day, cells were serum-starved overnight, followed 
by a 10 min treatment with 50 ng/ml HGF (Miltenyi Bio-
tec, Bergisch Gladbach, Germany). In some experiments, 
prior to HGF incubation cells were incubated with the anti-
MET llama VHH G2 [22] or cabozantinib (XL-184, Exe-
lixis, San Francisco, CA, USA) for 60 min.
Genetic analysis of E98
Genomic DNA from E98 cells was analyzed by semi-con-
ductor sequencing (IonPGM, Life Technologies) using the 
comprehensive cancer panel (Life Technologies) that tar-
gets 409 cancer-related genes. The IonPGM E98 library 
generation was performed according to the manufacturer’s 
protocol. In short, 10 ng of DNA per pool was amplified 
in 21 cycles by PCR using the Ion AmpliSeqTM master-
mix, followed by barcode and adapter ligation. Amplified 
products were purified with Agencourt AMPure XP beads 
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(Beckman Coulter Genomics, High Wycombe, UK). The 
library was diluted to 20 pM. Emulsion PCR was per-
formed using the Ion OneTouchTM 200 Template kit fol-
lowing the protocol of the Ion OneTouchTM System. Next, 
Ion Sphere Particles (ISPs) were recovered and enriched for 
template-positive ISPs using Dynabeads MyOne Streptavi-
din C1 beads (Life Technologies) in the Ion OneTouchTM 
ES instrument (Life Technologies). ISP enrichment was 
quantified using the Qubit 2.0 fluorometer (Life Technolo-
gies). Sequencing primer and polymerase were added to the 
final enriched spheres before loading onto an Ion 318 chip 
according to the Ion PGMTM 200 sequencing kit protocol. 
The gene copy number analysis was performed as follows. 
The relative number of sequence reads aligned to a spe-
cific gene was determined by dividing by the total number 
of aligned reads of E98, and was divided over the relative 
number of sequence reads of the same gene in non-neo-
plastic blood cells. The relative ratios are plotted in a graph 
based on the genomic position of the gene.
To perform confirmative mapping of the intronic dele-
tion in MET on the nucleotide level, genomic DNA was 
isolated from E98 and U87 cells using the DNeasy Blood 
& Tissue Kit (QIAGEN), according to the manufactur-
er’s protocol. 10 ng was subjected to PCR, using primer 
MET1997Fw (5′-CTCCTTGGAAATGAGAGCTG-3′, for-
ward, exon 6, genome location chr7q;g.116395517-36) and 
reverse primer MET2414Rev (5′-GGGATCTTCACGGT 
AACTG-3′, located in exon 9, CHR7q; g.116398565-45). 
Human genome sequence annotations are in all cases based 
on assembly hg19.
FISH
Formalin-fixed, paraffin-embedded sections (4 μm) on 
SuperFrost glass (dried >45 min at 56 °C) were deparaffi-
nized and rehydrated in ddH2O. After boiling in a micro-
wave in sodium citrate buffer (pH 6), slides were allowed 
to cool to RT, washed in ddH2O and incubated for 5 min 
in 10 mM HCl. Proteins were digested with pepsin (200 U/
ml, Sigma) for 15 min at 37 °C. Subsequently, slides were 
rinsed in 10 mM HCl and PBS and postfixed for 5 min in 
1 % paraformaldehyde (PFA, Merck)/PBS. Sections were 
washed in ddH20, dried and hybridized with 10 μl probe 
mix (1 μl cep7 Spectrum Green (06J37007) + 1 μl LSI 
MET Spectrum Red (06N05-001) + 7 μl hybridization 
buffer in MQ, all Vysis) under a cover slip. Sections were 
denatured at 80 °C for 10 min, followed by hybridization 
o/n at 37 °C in a Hybridizer (Dako). After removing the 
coverslip by soaking for 5 min in 2× SSC buffer (Maxim 
Biotech) at 42 °C, slides were washed 3 times in 2x SSC 
buffer at 73 °C, once in 2xSSC (5 min) and once in ddH2O. 
After dehydration in EtOH, slides were air-dried in the dark 
and mounted in Vectashield/DAPI (3 parts Vectashield/
DAPI + 1 part Vectashield, all vector). Slides were ana-
lyzed on a Leica Fluorescence microscope.
RT‑PCR and cloning
RNA was isolated from cell lines E98 and TOV112D-
MET [22] using TRIzol Reagent (Life Technologies) and 
reverse transcribed with MMLV-RT (New England Bio-
labs) using oligo-dT primers, according to the manufac-
turer’s instruction. HGF was PCR amplified from cDNA 
using Phusion High-Fidelity DNA polymerase (Finnzymes, 
ThermoFisher Scientific, Waltham, USA) and primers 
HGF-Fw204 (5′-CTGCAGCATGTCCTCC TGCA-3′) and 
HGF-Rv504 (5′-GAGGTCAAATTCATGGCCAA-3′) (30 
cycles, annealing at 55 °C, 20 s; extension at 72 °C, 20 s). 
Control PCR reactions were performed for housekeeping 
gene HMBS (Hydroxymethylbilane Synthase) using prim-
ers p361-Fw (5′-TGCCAGAGAAGAGTGTGGTG-3′) and 
p425-Rv (5′-GTTAAGCTGCCGTGCAACATC-3′).
MET open reading frames were PCR amplified from cDNA 
using Phusion DNA polymerase and primers flanking start and 
stop codons (MET173EcoR1-Fw: 5′-CGAATTCGATAAACC 
TCTCATAATGAAGG-3′ and MET4421NotI-Rv 5′-AGCGG 
CCGCCTATGATGTCTCCCAGAAGG-3′). PCR products 
were purified on agarose gel, digested with NotI and cloned 
as blunt-NotI fragment in pIRESneo-EcoRV-NotI (Clontech 
Laboratories, Inc, CA, USA) to yield pIRESneo-MET and 
pIRESneo-METΔ7–8. Full sequences were obtained by Sanger 
sequencing via the sequencing facility of Radboud UMC.
The extracellular parts of MET were PCR amplified from 
E98 and TOV-112D-MET cDNA using primers MET173E-
coR1-Fw and MET3028NheI-Rv (5′-CGCTAGCCTGATCT 
GGTTGAACTATT AC-3′), and cloned in vector pHLsec-
BAPHIS, a derivative from pHLsec-HIS (Addgene, Cam-
bridge, MA, USA). The resulting vector adds a biotin accep-
tor peptide and His-tag to the carboxyterminus of the MET 
extracellular domains, resulting in pHLsec-METED-BAPHIS 
and the E98-derived variant pHLsec-METΔ7–8ED-BAPHIS.
Transfection and protein purification
pIRESneo-MET or pIRESneo-METΔ7–8 were transfected 
into HEK-293T or TOV-112D cells in 6-well culture dishes 
(Greiner Bio-One, Krëmsmunster, Austria) using Fugene HD 
transfection reagent (Promega, Fitchburg, WI, USA) accord-
ing to the manufacturers’ instructions. After 48 h, cell mon-
olayers were washed with PBS and cell extracts prepared in 
RIPA buffer containing protease and phosphatase inhibitors 
(Cell Signaling Technology, CST, Danvers, MA, USA).
In separate experiments, pHLsec-METΔ7–8ED-BAPHIS 
or pHLsec-METED-BAPHIS were cotransfected in a 1:1 
ratio with the biotin-ligase expression construct pDIS-
PLAY-BirA-ER (Addgene) in HEK293T cells and cells 
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were cultured in the presence of 10 μM biotin (Sigma-
Aldrich, St Louis, MO, USA). After 48 h, cytosolic extracts 
were made in RIPA buffer, and medium (1 ml) was mixed 
with 100 μl Ni–NTA Sepharose slurry (IBA, Goettingen, 
Germany). After a 1 h incubation at 4 °C, Ni-beads were 
washed with buffer (500 mM NaCl, 50 mM phosphate 
buffer, pH 7.4) and loaded onto a poly-prep column (Bio-
Rad, Hercules, CA, USA). After washing off specifically 
bound proteins with 2 ml 10 mM imidazole, His-tagged an 
biotinylated MET extracellular domains were eluted with 
0.5 ml 0.5 M imidazole, and dialysed o/n at 4 °C to 50 mM 
TRIS/150 mM NaCl pH 7.5.
MET downregulation via short hairpin RNAs
To create MET knockdown constructs, shMET1 (GTATG 
TCCATGCCTTTGAA) and shMET2 (GTATGTCCATGCC 
TTTGAA) oligonucleotide heteroduplexes were ligated in 
pENTR/U6 vector and subsequently Gateway-cloned into 
pLenti6/BLOCK-iT-DEST-TagRFP according to the manu-
facturer’s protocols (Invitrogen). Generation of lentiviruses 
was done in HEK293FT cells as described previously [7].
Protein analysis
RIPA extracts (20–40 µg protein per lane) and purified 
His-tagged proteins from conditioned media (equivalent 
of 20 µl conditioned medium) were subjected to PAGE on 
8–10 % polyacrylamide gels and western blotting accord-
ing to standard procedures. Nitrocellulose blots (Whatman 
Optitran BA-S85, GE Healthcare, Little Chalfont, UK) were 
blocked with PBS/Odyssey Blocking Buffer (LI-COR Bio-
sciences, Lincoln, NE, USA) (1:1), followed by overnight 
incubation with primary antibodies at 4 °C. Antibodies used 
were against MET N-terminus (clone EP1454Y, Epitomics, 
Abcam, Cambridge, UK), MET C-terminus (clone D1C2), 
phosphorylated (P)-MET (Y1234/1235, clone D26), P-AKT 
(S473, clone D9E), P-ERK1/2 (T202/Y204, clone 20G11) 
(all CST), GAPDH (clone 6C5, Abcam), and α-tubulin 
(clone 236-10501, Molecular Probes, Life Technologies). 
Biotin groups and primary antibodies were visualized using, 
respectively, streptavidin-680 (Molecular Probes, Life Tech-
nology) and appropriate secondary antibodies [goat-anti-rab-
bit-IRDye800 (Rockland Immunochemicals, Gilbertsville, 
PA, USA) or Alexa Fluor 680 goat-anti-mouse IgG (Molecu-
lar Probes, Life Technologies)]. Blots were scanned on the 
Odyssey imager (LI-COR Biosciences).
Protein domain modeling
A homology model for the new hybrid IPT-domain using 
the WHAT IF & YASARA Twinset was generated [31, 
60]. We used the experimentally solved 3D structure 2uzx, 
which contains the human tyrosine kinase MET. The first 
60 residues of the hybrid domain are identical to this struc-
ture, whereas the following 38 residues were modeled 
based on homology between the 2 domains.
Confocal microscopy
E98 and U87 cells, grown on Nunc Lab-Tek chamber slides 
(Sigma-Aldrich) to 40 % confluence, were fixed with 2 % 
PFA in 0.1 M phosphate buffer (pH 7.4) for 15 min at RT, 
followed by three washes with PBS, 30 min glycine incu-
bation (100 mM in PBS) to quench PFA-induced auto-
fluorescence, three PBS washes and permeabilization with 
digitonin for 10 min (100 μM in PBS). Aspecific binding 
was blocked by incubation with 20 % normal goat serum 
in PBS/1 %BSA for 20 min, and cells were incubated over-
night at 4 °C in a humidified chamber with PBS/1 %BSA 
containing (combinations of): mouse monoclonal anti-
CD44 antibody (as a surface marker, clone Hermes-1, 
ThermoFisher Scientific); rabbit anti-MET (clone D1C2, 
CST); rabbit anti-P-MET (clone D26, CST); mouse anti-
EEA-1 (clone 14/EEA1, BD Biosciences, early endo-
some marker); anti-CLIMP-63 (clone G1/296, rough ER 
marker, a kind gift of J. Fransen). Primary antibodies were 
detected using Alexa Fluor 488- or 594-labeled second-
ary goat-anti-mouse and Alexa Fluor 488- or 568-labeled 
goat-anti-rabbit IgGs (all Life Technologies), 1:200 diluted 
in PBS/1 %BSA. Q-nuclear deep red (1:200, Life Tech-
nologies) was used to stain nuclei, and cells were mounted 
in Fluoromount G with DAPI (Southern Biotech, Birming-
ham, AL, USA). Cells were analyzed using a confocal laser 
scanning microscope (Leica SP2 CLSM) and Leica confo-
cal software.
Biotinylation assay
E98 and A549 cells were allowed to adhere and grown to 
80 % confluence in a 6-well plate (Cellstar, Greiner Bio-
One, Kremsmünster, Austria). Cells were washed 3 times 
with ice-cold PBS and incubated for 30 min at 4 °C with 
0.5 mg/ml EZ-Link Sulfo-NHS-LC-Biotin (ThermoFisher 
Scientific). This compound does not penetrate cells and 
biotinylation is therefore confined to exposed membrane 
proteins. In parallel, Tris-free RIPA extracts, prepared 
from equivalent numbers of E98 or A549 cells by repeated 
washing over Amicon Ultra K10 centrifugal filters (Merck 
Millipore, Billerica, MA, USA), were treated similarly to 
biotinylate all cellular proteins. The reaction was quenched 
by washing cells or cytosolic proteins three times with 
100 mM glycine/PBS and two times with PBS (using K10 
columns in the case of protein lysates). Intact biotinylated 
cells were then subjected to lysis with RIPA buffer. Pro-
tein concentrations in all lysates were determined using 
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the BCA protein concentration assay (ThermoFisher Sci-
entific). MET was immunoprecipitated from 200 µg total 
protein in a volume of 200 μl using anti-MET (1:50, clone 
D1C2, CST) for 1 h at 4 °C. Immune complexes were cap-
tured by incubation for 30 min at 4 °C with 10 μl prot A 
agarose slurry (Roche Diagnostics, Basel, Switzerland), 
followed by centrifugation (14,000 rpm, 4 min) and three 
PBS washes. Immune complexes were solubilized by heat-
ing (5 min 95 °C) in 30 μl 2× SDS-PAGE sample buffer 
(0.2 % SDS, 62.5 mM Tris–HCl pH 6.8, 10 % glycerol 
and 0.2 μM DTT). Samples were subjected to 10 % SDS-
PAGE and western blotting as described above.
RT‑PCR analysis
Glioma tissues (n = 80) were obtained from the Rad-
boud UMC and from the University of Cologne. Sarcoma 
(n = 25) and castration-resistant prostate cancer (CRPC) 
tissues (n = 43) were obtained from Radboud UMC. RNA 
was isolated from tissues using the mirVANA RNA isola-
tion kit (Life Technologies) according to standard proce-
dures. For cDNA synthesis, 1 μg RNA was reverse tran-
scribed using the Quantitect Reverse Transcription Kit 
(QIAGEN, Venlo, The Netherlands) using hexanucleotides. 
To distinguish wtMET from METΔ7−8-transcripts, a PCR 
was performed in AmpliTaq Gold 360 mastermix (Applied 
Biosystems, Life Technologies) using primer MET1997Fw 
(5′-CTCCTTGGAAATGAGAGCTG-3′, forward, located 
in exon 6), and primer MET2342Rv (5′-CAGTTGAAATG-
GTTTGGGCTG-3′, reverse, located in exon 9). This PCR 
results in a 105-bp product for METΔ7–8 and a 345-bp 
product for wtMET. Conditions were: denaturation 95 °C, 
followed by 35 cycles of 95 °C denaturation; annealing at 
58 °C, 30 s; elongation at 72 °C, 1 min. A final elongation 
step of 7 min was done at 72 °C.
Results
E98 MET protein is auto‑activated in an 
HGF‑independent fashion
Our previous experiments have shown that MET in ortho-
topic E98 xenografts is phosphorylated in tumor cells in a 
homogeneous fashion (Fig. 1a, see also [42]). In vitro, E98 
cells also show high levels of phosphorylated MET when 
grown under serum-free conditions (Fig. 1b). HGF treat-
ment did not further increase phosphorylation levels of 
MET, in contrast to A549 control cells in which HGF was 
required for MET activation. MET phosphorylation in E98 
cells was not the result of endogenous HGF expression as 
revealed by RT-PCR analysis (Fig. 1c), while analysis of 
E98 xenograft RNA revealed the presence of mouse HGF 
only, as determined by Sanger sequencing (not shown). 
Since mouse HGF is not an activating ligand for human 
MET [62], we conclude that constitutive activation of MET 
in E98 cells and xenografts is not the result of an autocrine 
HGF-activation loop.
E98 cells express a truncated version of an amplified 
MET gene
To examine the underlying mechanism of MET auto-acti-
vation in this model, we PCR-cloned MET cDNA from 
E98 cells, using primers flanking the open reading frame 
(ORF, NM_000245.2). The MET PCR product from E98 
was 240 bp smaller than that from U87 and CaCo2 cDNA 
(Fig. 2a), and Sanger sequencing analysis revealed an in-
frame deletion of nt 2050–2289 in the coding sequence, 
corresponding to exons 7 and 8. The same transcript was 
also found in E98 xenografts (not shown). Genomic analy-
sis of E98 cells using semi-conductor sequencing revealed 
high copy MET amplification (Fig. 2b). Average amplifica-
tion of MET (except for exons 7/8) was about 14-fold. FISH 
analysis using probes specific for MET and chromosome 
7 centromere confirmed the amplification (Fig. 2c). Con-
sistent with Sanger sequencing, amplicons in exon 7 and 
the first part of exon 8 were absent (see insert in Fig. 2b), 
suggesting that the lack of exons 7 and 8 results from a 
genomic rearrangement (similar to the EGFR variant III 
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Fig. 1  MET is constitutively activated in the E98 cell line and xen-
ograft model. a Sections of an intracranial E98 xenograft were sub-
jected to immunohistochemistry for P-MET (upper panel, brown 
staining). A matching H&E staining is shown as reference. Note that 
tumor shows diffuse infiltration in the brain parenchyma and that the 
tumor cells are highly positive for this activated MET. b Western blot 
analysis of MET expression in serum-starved E98 and A549 cells in 
absence of presence of HGF. Note that the processed form of MET 
(arrowhead) in E98 is somewhat smaller than that of A549 while 
the preform is predominantly present in E98 (arrow). α-Tubulin was 
used as a loading control. c RT-PCR for HGF on E98, TOV-112D and 
HEK-293T cell line cDNA. HMBS was used as a control housekeep-
ing gene
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[15]), instead of alternative splicing. PCR on genomic 
DNA using exon 6- and 9-specific primers resulted in 
amplification of a 910-bp fragment (predicted size from the 
wild-type allele, present in U87, is 3014 bp, see Fig. 2d). 
Sequencing of this product revealed an intronic deletion of 
2114 bp (between position g.116 395 653 located in intron 
6, and 116 397 766, located in exon 8). This deletion results 
in an intact splice donor site from exon 6, juxtaposed to the 
exon 9 splice acceptor site, and explains the lack of exons 
7 and 8 in the resulting mRNA (Fig. 2e). Of note, a wtMET 
allele could not be detected in E98 cells (Fig. 2d).
In the MET protein, this rearrangement leads to loss 
of the C-terminus of IPT1 and the N-terminus of IPT2 
(Fig. 3a). Yasara modeling, using X-ray crystallographic 
data of the MET ectodomain, predicts the formation of a 
novel IPT, composed of the remaining parts of IPT1 and 
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Fig. 2  E98 MET contains an intronic deletion, resulting in a trun-
cated transcript. a RT-PCR on cDNA from different cell lines using 
full-length MET primers, using HMBS as a housekeeping gene for 
reference. b Ion-torrent sequencing analysis exposes a high-copy 
amplification of MET in E98 DNA. Plotted on the x-axis are all 409 
genes sequenced, in chromosomal order. The number of reads per 
gene was compared to blood-obtained DNA from a glioma patient 
as a reference. The dotted line represents the level of heterozygous 
losses, as can be seen for the X-chromosome (the reference blood 
sample was female, while the tumor DNA was male). The inset 
shows the relative number of reads per MET exon. Note the loss of 
exon 7 and part of exon 8. c FISH analysis of the number of MET 
(red) and chr.7 centromere (green) copies in the genome of an E98 
xenograft. d Amplification of MET using exon 6- and 9-specific prim-
ers on genomic DNA of E98 and U87 cells. METΔ7–8 and wtMET 
amplification leads to 910- and 3041-bp products in E98 and U87, 
respectively. e Schematic overview of the METΔ7–8 deletion found in 
E98 cDNA. Splicing of exon 6 to exon 9 is indicated with the dotted 
orange lines. The orange solid line represents the deletion
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2. Interestingly, in the new IPT1/2 fusion, a small stretch 
of 5 extra amino acids loops out towards the Sema domain 
(Fig. 3b, arrow).
METΔ7–8 is aberrantly processed
MET is synthesized as a 190-kDa precursor protein which 
is proteolytically cleaved by furin between residues 307 
and 308, to yield an extracellular α-chain of approximately 
45 kDa, covalently linked via a disulfide bridge to the 
transmembrane β-chain. Reducing SDS-PAGE, followed 
by Western blot analysis of E98 cell extracts showed that 
the majority of MET protein was in a 180-kDa phospho-
rylated form, corresponding to the uncleaved truncated 
preform (Fig. 1b, arrow). In contrast, in A549 cells the 
matured cleaved MET protein was the predominant form 
(arrowhead in Fig. 1b). To investigate whether this was a 
specific feature of E98 cells, we analyzed the protein struc-
ture in cells after transfection with the full-length cDNAs 
encoding METwt or METΔ7–8. In both HEK-293T and 
TOV-112D cells, wtMET was properly processed to an α- 
and β-chain, indicating that these cells are not defective in 
furin-mediated processing. In contrast, METΔ7–8 was pre-
dominantly present in the uncleaved preform in both cell 
types (Fig. 4a, arrow). Thus, improper MET cleavage is an 
intrinsic property of METΔ7–8. Overexpression studies in 
HEK-293T and TOV-112D cells resulted in phosphorylated 
Y1234/1235 residues in both METwt and METΔ7–8 proteins 
(Fig. 4a, P-MET). Because both cell lines produce HGF 
(Fig. 1c), this may be a result of HGF-dependent autocrine 
activation.
MET is cleaved by the endoprotease furin, which is 
localized predominantly in the trans-Golgi network, but 
also in vesicles and near the plasma membrane [8, 29, 
52]. To test whether the inefficient cleavage of METΔ7–8 
in E98 cells is related to intracellular transport defects, we 
analyzed the subcellular localization of METΔ7–8 in detail 
via confocal microscopy. METΔ7–8 did not co-localize 
SEMA
A
B
IPT1wt
IPT1/2∆7-8
IPT2wt
Fig. 3  Predicted protein structure of METΔ7–8. a Schematic overview 
of MET and METΔ7–8. The red lined box represents the deletion, 
comprising parts of the IPT1 and 2 domains (represented by the red 
and yellow boxes, respectively, in METΔ7–8). b Yasara modeling of 
the remaining IPT1 and 2 domains in METΔ7–8 was performed based 
on wtMET IPT1. The wtMET SEMA domain and IPTs are shown in 
blue, with the novel putative IPT domain consisting of IPT1 (red) and 
2 (yellow) of METΔ7–8, superimposed on wtMET. An enlargement of 
the fusion part in the overview figure (arrow) is shown in the right 
panel. The arrow indicates the additional loop in red that is formed 
by the novel IPT domain
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with the cell surface marker CD44 and was confined to 
the cytosol (Fig. 4b). In contrast, in U87 cells METwt did 
co-localize with CD44. Additional intracellular staining 
in U87 cells reflects de novo synthesized material that is 
being processed for constitutive secretion. Immunostain-
ings with the early endosome marker EEA-1 and the rough 
endoplasmic reticulum (RER) marker CLIMP-63 sug-
gested that METΔ7–8 in E98 cells is predominantly retained 
in the RER (Fig. 4c).
To confirm the absence of cell surface expression of 
METΔ7–8 on E98 cells, we labeled intact E98 cells or cell 
lysates with NHS-biotin and immunoprecipitated MET 
D
E intracell. secreted  
∆78 wt ∆78 wt
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Fig. 4  Aberrant processing and localization of METΔ7–8. a Western 
blot analysis of MET expression in HEK-293T and TOV-112D cells, 
transfected with pIRESneo-MET or pIRESneo-METΔ7–8. Note that 
HEK-293T cells have endogenous MET expression. As a loading 
control, α-tubulin was used. b Analysis of MET localization in E98 
by confocal microscopy, using CD44 as a membrane marker (green) 
in combination with C-terminal MET antibodies (red), or phospho-
rylated MET (1234/1235, red) as indicated. U87 cells were also 
analyzed for MET/CD44 colocalization for comparison. Q-nuclear 
deep red stain was used to stain all nuclei. c Subcellular localization 
of MET (green) with early endosome and RER markers EEA-1 and 
CLIMP-63 (both in red) in E98 cells. d Western blots of biotinylated 
intact E98 and A549 cells or of biotinylated cell lysates. MET was 
immunoprecipitated and analyzed on western blot for biotinylation, 
as described in the materials and methods section. The α-chain of 
MET is shown. e His-tagged ectodomains of both wild-type MET 
and METΔ7–8, biotinylated via a biotin-acceptor peptide at the car-
boxyterminus, were expressed in HEK-293T cells. Ni-purified culture 
media and extracts of the transfected cells were used to analyze MET 
localization. Both fractions were subjected to western blotting using 
N-terminal MET antibodies, recognizing both the preform and the 
cleaved α-portion of the ectodomain, and directly labeled streptavidin 
to visualize the preform and the β-chain. GAPDH was used as a load-
ing control for the RIPA extracts (red signal at 36 KDa)
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using specific antibodies, followed by SDS-PAGE/West-
ern blot and staining for biotin and MET. Whereas METs’ 
N-terminal α-chain was readily biotinylated in E98 cell 
lysates, no detectable MET biotinylation occurred when 
intact cells were labeled (Fig. 4d, lane 1). In contrast, bioti-
nylated MET was readily detected in A549 cells upon labe-
ling of intact cells, as shown by the biotin-labeled α-chain 
(Fig. 4d, lane 3). Thus, these data confirm that METΔ7–8 is 
predominantly localized intracellular and is poorly exposed 
on the cell surface of E98 cells.
To further confirm a defect in intracellular trafficking of 
METΔ7–8, we analyzed secretion patterns of extracellular 
domains of wtMET or METΔ7–8 (ending with residue D929, 
numbering according to MET variant 2 (NP_000236.2), 
containing a C-terminal biotin tag. Whereas the extra-
cellular domain of wtMET was properly processed and 
secreted into the culture medium (as illustrated by the 
presence of the 309-929 biotinylated extracellular β-chain 
and the MET25-308 α-chain, Fig. 4e, lane 4), no secreted 
MET products were found in medium of cells, transfected 
with the METΔ7–8 ectodomain (Fig. 4e, lane 3). Instead, 
all biotinylated MET products were located intracellularly 
(Fig. 4e, lane 1).
185‑kDa METΔ7–8 is not affected by antagonistic 
anti‑MET antibodies but is inhibited by cabozantinib
It was previously reported that incubation of A549 cells 
with VHH G2, a recombinant single-domain llama anti-
body against MET, results in low MET activation levels, 
while inhibiting the strong activation which is induced by 
HGF [22]. To test whether and how G2 affects phospho-
rylation of METΔ7–8, we treated serum-starved E98 cells 
with G2, either followed or not followed by HGF, using 
A549 cells as control. As shown in Fig. 5, HGF did not 
increase overall MET phosphorylation levels, although, 
interestingly, a slight activation was seen in the minority 
of processed β-fragment of MET. For G2, a similar effect 
was observed. Consistent with high overall MET phospho-
rylation levels in all samples, neither G2 nor HGF treat-
ment resulted in altered levels of P-AKT and P-ERK1/2, 
both targets of MET. In A549 cells G2 and HGF induced 
MET phosphorylation, which increased levels of P-AKT 
and P-ERK1/2. Thus, in contrast to A549 cells that express 
METwt, E98 cells are not responsive to antibodies against 
or ligands of MET. However, both E98 and A549 cells 
responded well to the MET tyrosine kinase inhibitor cabo-
zantinib (Fig. 5).
Prevalence of METΔ7–8
Data mining of the COSMIC and TCGA databases did not 
uncover the intronic deletion in gliomas and other tumor 
types (not shown). Intragene deletions spanning multiple 
exons are, however, in general more difficult to recognize 
in whole-exome sequencing (WES). Furthermore, the cov-
erage of the exact location of the deletion is poor in the 
mostly used WES protocols, and as can be seen in Fig. 2b, 
even targeted sequencing reveals the mutation only after 
detailed bioinformatic analysis. We, therefore, assume that 
detection of METΔ7–8 requires dedicated PCR protocols.
PCR with deletion-spanning primers revealed the pres-
ence of the deletion-specific 105-bp fragment in E98 
cDNA, while a number of other cell lines presented with 
the wt 345-bp amplicon only (Fig. 6a). Since frozen mate-
rial from the patient tumor that was used to generate E98 
is unavailable, we could unfortunately not obtain genomic 
DNA and cDNA of sufficient quality to confirm the pres-
ence of the mutation in the originating tumor. We did how-
ever perform immunohistochemistry on formalin-fixed, 
paraffin-embedded tumor material from this patient and 
observed a highly heterogeneous staining for MET, with 
only a small percentage of strongly positive tumor cells, 
apparently with intracellular staining (Fig. 6b). Of note, 
such immunostainings cannot discriminate between METwt 
and METΔ7–8. FISH analysis confirmed the presence of the 
MET amplification in the original tumor (Fig. 6c).
To investigate the prevalence of the METΔ7–8 mutation 
further, we performed the exon 6–9 PCR on cDNA, gen-
erated from a series of gliomas (n = 102) and a number 
of other tumor types in which MET has been suggested to 
play an important role (castration-resistant prostate carci-
nomas, n = 43; Ewing sarcoma, n = 21; rhabdomyosar-
coma, n = 22) [24, 28]. METΔ7–8 was found in 6 out of 102 
gliomas, both grade III and IV (5.8 %; 2 out of 5 anaplastic 
oligodendrogliomas, 2 out of 16 anaplastic astrocytomas 
and 2 out of 61 glioblastomas), and was not detected in 
the other tumor types tested (Table 1). All grade III tumors 
with METΔ7–8 were IDH1-R132H mutated. Most tumors 
GAPDH
P-AKT
P-MET
uncleaved -
cleaved β -
E98 A549
- G2 XL HGF - G2 XL HGF
P-ERK1/2--
Fig. 5  METΔ7–8 is blocked by TKIs but not by inhibiting antibodies. 
E98 and A549 cells were left untreated or treated with the MET VHH 
G2, cabozantinib (XL; MET/VEGFR2 inhibitor), or HGF. Protein 
lysates were analyzed for MET, AKT and ERK1/2 (p42/44) phospho-
rylation. GAPDH was used as a loading control. Note the prominent 
uncleaved MET protein in E98, which is absent in A549 cells
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that contained the mutation were heterozygous, contain-
ing also the wild-type transcript (example in Fig. 6d). Fur-
ther research with higher numbers of patients is needed to 
investigate any correlations between METΔ7–8 and other 
molecular aberrations.
Sanger sequencing of the smaller PCR products of one 
patient with glioma confirmed the deletion of exons 7 and 
8 (not shown). Of note, due to the lack of high-quality 
genomic DNA from these clinical samples we could not 
discriminate in these samples whether METΔ7–8 resulted 
from a mutation or from exon skipping or alternative splic-
ing, such as suggested for MET variants lacking exon 10 or 
14 [37].
Discussion
A major problem in glioma treatment is diffuse growth 
in the neuropil, and it has been suggested that the MET 
oncogene is causally involved in this phenotype in sub-
sets of tumors [16]. Several signal transduction pathways 
that are induced by MET activation are shared with other 
tyrosine kinase receptors and it is increasingly recognized 
that activation of MET bypasses the need for EGFR activa-
tion, generating resistance to EGFR-targeted therapies [13]. 
Also, there is an interesting crosstalk between MET and 
EGFR: the EGFR variant III (EGFRvIII) stimulates expres-
sion of both MET and its ligand HGF, possibly contribut-
ing to oncogenicity of EGFRvIII [16], but this phenomenon 
is counteracted by EGF-mediated activation of wild-type 
EGFR in the same complex [33].
We previously reported that MET is crucially implicated 
in proliferation, survival and migration of (EGFR-negative) 
E98 glioma cells in vitro. To further investigate the involve-
ment of MET in the biological behavior of E98 cells, we 
Fig. 6  METΔ7–8 is expressed in 
glial tumors. a PCR analysis of 
cell line cDNAs using primers 
located in exon 6 and exon 9. 
This PCR results in a product of 
105 bp for the METΔ7–8, while 
wtMET gives a 345-bp product. 
b Immunohistochemical stain-
ing for MET of the patients’ 
tumor from which the E98 cell 
line has been generated. c FISH 
analysis of the number of MET 
(red) and chromosome 7 (green) 
copies in the original E98 
patient tumor. d PCR analysis 
for METΔ7–8 on a random set 
of glioma biopsies. Note that in 
tumors with METΔ7–8 expres-
sion, also wtMET is observed
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Table 1  METΔ7–8 expression in glioma, sarcoma and CRPCs
The incidence of METΔ7–8  in different subtypes and malignancy 
grades of diffuse glioma, sarcomas and castration-resistant prostate 
carcinomas (CRPC)
O-II oligodendroglioma (WHO grade II), O-III oligodendroglioma 
(WHO grade III), A-II astrocytoma (WHO grade II), A-III anaplastic 
astrocytoma (WHO grade III), GBM glioblastoma
Tumor type Δ7/8 occurrence
Glioma 6/102 (5.8 %)
 O-II 0/3
 A-II 0/7
 OA-II 0/5
 O-III 2/5 (40 %)
 A-III 2/16 (12.5 %)
 OA-III 0/5
 GBM 2/61 (3.3 %)
Sarcoma 0/25
 Ewing tumor 0/5
  Cell line 0/3
 Rhabdo tumor 0/15
  Cell line 0/2
CRPC 0/43
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attempted to knock down the protein by a lentiviral shRNA 
approach. Attempts to generate stable MET knockdowns 
using 2 different MET shRNAs failed since both shRNA 
encoding lentiviruses were lethal to E98 cells, in contrast to 
control viruses (data not shown). In agreement with a cru-
cial role of MET for cell survival, we showed that treatment 
with the MET tyrosine kinase inhibitor cabozantinib pro-
longs survival of mice carrying orthotopic E98 xenografts 
[42]. Based on the observation that the pattern of MET 
phosphorylation in E98 xenografts was remarkably homo-
geneous in the absence of its ligand HGF, we analyzed 
the MET product in E98 cells in more detail and found 
that the protein is expressed as a truncated product, which 
lacks effective furin cleavage and is predominantly retained 
intracellular in its active, phosphorylated form. The trunca-
tion generates a novel IPT domain consisting of a fusion 
between the carboxyterminus of IPT1 and the amino termi-
nus of IPT2. Modeling of the novel fusion IPT domain sug-
gests that it adopts a similar structure as the IPT domains 
in wild-type MET, although a small stretch of extra amino 
acid residues is accommodated in a loop, extending towards 
the Sema domain. Since this loop approaches the furin 
cleavage site in the Sema domain, it may directly affect 
furin cleavage. Interestingly, the colorectal adenocarci-
noma cell line Lovo lacks furin protease and consequently 
cannot properly process MET [40]. In this cell line, the 
unprocessed preform is still expressed on the cell surface, 
binds HGF and is capable of signaling. Thus, defective 
processing alone does not explain intracellular retention 
of METΔ7–8 and we therefore hypothesize that the novel 
IPT1-2 fusion domain in METΔ7–8 is involved in defective 
furin cleavage, intracellular retention of the uncleaved per-
form and auto-activation of the uncleaved preform.
Recently, effects of various activating mutations in 
the MET TK domain have been analyzed in detail. These 
mutants are expressed on the cell surface but are subject 
to increased rates of turnover, resulting in accumulation in 
early endosomes where they can still signal [27]. METΔ7–8 
did not accumulate in early endosomes, suggesting that the 
underlying mechanism of intracellular retention is different 
[41]. Our confocal microscopy and biotinylation experi-
ments strongly suggest that only the very small fraction of 
METΔ7–8 that is cleaved reaches the cell membrane, but 
this fraction is insignificant with respect to the auto-active 
component in the cytosol.
From a genetic perspective, the METΔ7–8 mutant resem-
bles the auto-active EGFRvIII variant which occurs con-
comitant with EGFR amplification in 25–64 % of all 
GBMs [51, 59]. This variant results from a genetic deletion 
of exons 2–7 and its activation is also independent of the 
ligands EGF or TNFα. Like the EGFRvIII mutation [15], 
the METΔ7–8 alteration appears to be restricted to only 
few cancer types, as we detected it in glioma but not in a 
number of other tumor types. The mutation was detected 
in grade III gliomas of both oligodendroglial and astrocytic 
origin and GBMs. Investigations of METΔ7–8 expression in 
other tumor types is however warranted and is ongoing in 
our lab.
Another example of a tyrosine kinase receptor which 
often carries deletions in GBM is PDGFRA. Forty per-
cent of the GBMs with amplified PDGFRA contain an in-
frame deletion in the ectodomain, leading to constitutive 
activation of the TK domain [46]. Recently, also in pedi-
atric high-grade gliomas, ligand-independent and tumo-
rigenic in-frame PDGFRA deletion variants have been 
reported [47, 58]. Data on the subcellular localization of 
such mutated oncoreceptors are frequently lacking, and our 
data call for in-depth analysis of the cellular localization 
of receptors that are considered targetable. Interestingly, 
activating mutations in the RON tyrosine kinase receptor 
have been identified which resemble the METΔ7–8 mutation 
in that it also involves the first IPT domain [39]. Of note, 
these alterations do not lead to a loss of expression at the 
cell surface.
Importantly, we did not detect a METwt transcript in E98 
cells, in contrast to the clinical gliomas which were ana-
lyzed in this study and which all showed abundant wtMET, 
also in METΔ7–8 tumors. We formally cannot exclude that 
the wild-type MET amplicons in our PCR derive from 
‘contaminating’ non-neoplastic stromal cells in the tumor 
biopsies that were tested. There may, however, be another 
explanation for the relatively low levels of METΔ7–8 in 
clinical tumors: in the patient tumor from which the E98 
model was generated, a low percentage of MET-express-
ing tumor cells was detected, although it is impossible to 
determine whether these cells carry the METΔ7–8 mutation 
because the antibodies used do not discriminate between 
MET and METΔ7–8. It is tempting to speculate that during 
the generation of the E98 model, a small subset of METΔ7–8 
tumor cells in the primary tumor experienced a growth 
advantage, ultimately resulting in clonal outgrowth during 
xenograft formation. This scenario fits with the notion that 
clinical tumors not only show inter- but also intratumoral 
heterogeneity [54], and derived preclinical tumor models 
may only be representative for the most malignant popula-
tion of tumor cells.
Expression of METΔ7–8 may have important conse-
quences for choice of therapy. MET is increasingly rec-
ognized as an important target in multiple tumor types, 
including glioma, and therapeutic antibodies against HGF 
or the HGF binding site on MET have been developed. 
Since HGF is not involved in METΔ7–8 activation and 
METΔ7–8 is retained intracellular, MET-mutated cells will 
not be responsive to these therapies. Indeed, we were able 
to show that E98 cells do not respond to the anti-MET 
VHH G2. Selection of MET-mutated cells in tumors that 
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initially respond to antibody-based MET-directed treatment 
is expected to result in recurrence of treatment-resistant 
clones. In this respect, it will be important in future stud-
ies to assess the occurrence of the Δ7–8 mutation in paired 
samples of primary and recurrent tumors after MET anti-
body-based therapies, but also anti-EGFR therapies since 
cells may use METΔ7–8 to bypass EGFR signaling [3, 53]. 
With this in mind, the use of specific tyrosine kinase inhibi-
tors of MET may have preference over antibody-based 
therapy for resistant tumors, at least in the ones that are 
KRAS and RAF wild type, [3, 21, 57, 61] since METΔ7–8 
is sensitive to these inhibitors [42]. Such inhibitors have 
already shown to improve overall survival of patients with 
non-small cell lung carcinoma with MET amplification and 
renal papillary carcinoma with MET mutations [11, 45]. 
A recent clinical study with anti-MET antibody MetMab 
for lung cancer failed to meet the primary endpoint of pro-
longed survival [55]. A study of MET mutations and intra-
cellular localization patterns in this patient group may be 
highly informative for future therapeutic directions [23].
In conclusion, we describe a highly active, non-ligand-
dependent mutant of MET in 6 % of gliomas, which is not 
exposed on the cell surface and is predicted to be non-targ-
etable with therapeutic antibodies against MET and/or HGF.
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